Compare · ACHV vs MYMD
ACHV vs MYMD
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and MyMD Pharmaceuticals Inc. (MYMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and MYMD operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ACHV carries a market cap of $691.0M.
- ACHV has hit the wire 3 times in the past 4 weeks while MYMD has been quiet.
- ACHV has more recent analyst coverage (11 ratings vs 0 for MYMD).
- Company
- Achieve Life Sciences Inc.
- MyMD Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $691.0M
- -
- 1M return
- -6.41%
- -
- 1Y return
- +46.41%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 3
- 0
- Recent ratings
- 11
- 0
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
MyMD Pharmaceuticals Inc.
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
Latest ACHV
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
- Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
- Stifel initiated coverage on Achieve Life Sciences with a new price target
Latest MYMD
- TNF Pharmaceuticals Trades Under New Ticker "TNFA"
- TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
- MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
- MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
- SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Friscia Stephen
- Latest Key Hires & Board Changes In Cannabis Industry: Canopy Growth, Acreage And More
- MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-3 filed by MyMD Pharmaceuticals Inc.
- Amendment: MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement